4.3 Article

Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients

期刊

出版社

JOHN WILEY & SONS LTD
DOI: 10.1002/prp2.764

关键词

6-mercaptopurine; AZA thioprine; inflammatory bowel disease; xanthine oxidase

资金

  1. National Major Projects for Science and Technology Development
  2. Science and Technology Ministry of China [2009ZX09304-003]
  3. National Nature Science Fund of China [30572231, 30873124, 30873125]
  4. Hainan Medical University
  5. Ministry of Education [KLET-201908]
  6. Science, Technology and Innovation Commission of Shenzhen Municipality [JCYJ20190809155603683]
  7. Key Laboratory of Emergency and Trauma

向作者/读者索取更多资源

The study revealed that patients with lower XO activity in thiopurine therapy are more likely to experience adverse effects, especially leukopenia. However, no significant correlation was found between XO activity and other adverse effects.
Xanthine oxidase (XO) competes with thiopurine S-methyltransferase (TPMT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) to metabolize azathioprine (AZA)/6-mercaptopurine (6-MP) in vivo. A retrospective investigation was performed to detect the activity of XO in thiopurine curative Chinese inflammatory bowel disease (IBD) patients. We also evaluated whether a relationship between XO activity and incidence of thiopurine-induced adverse effects (AEs) existed. Clinical data and blood samples were collected from 140 IBD patients before receiving AZA/6-MP therapy, and the erythrocyte XO activity was measured. The XO activities of all patients were 20.29 +/- 4.43 U/g Hb. No sex difference in XO activity was observed (p = .728), and the XO activity showed no difference between the UC and CD patients (p = .082). AEs were observed in 41 (29.3%) patients including leukopenia (26, 18.57%), gastrointestinal intolerance (11, 7.86%), flu-like symptom (5, 3.57%), alopecia (5, 3.57%), and hepatotoxicity (1, 0.71%). XO activity was significantly lower in the patients with AEs than in those without AEs (18.40 +/- 3.73 vs. 21.07 +/- 4.48 U/g Hb, p = .001), especially in the patients with leukopenia (18.29 +/- 3.68 vs. 21.07 +/- 4.48 U/g Hb, p = .004). However, no significant difference in XO activity was found between patients with and without other AEs. Decreased XO activity was observed in the patients who developed flu-like symptoms (17.58 +/- 3.50 U/g Hb) and alopecia (18.67 +/- 2.91 U/g Hb) compared to those who did not, although the differences did not reach statistical significance. These findings suggested that patients with low XO expression might have a high risk of thiopurine-induced toxicity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据